Molecular docking and in vivo studies of liquiritin against acute myocardial infarction via TLR4/MyD88/NF-κB signaling

Peng Zhou1,2,3*, An-lu Shen1#, Pei-pei Liu1, Shu-shu Wang1*, Liang Wang1,2,3*

1School of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei, People's Republic of China; 2Institute of Integrated Chinese and Western Medicine, Anhui Academy of Chinese Medicine, Hefei, People's Republic of China; 3Anhui Province Key Laboratory of Chinese Medicinal Formula, Hefei, People's Republic of China

# These authors contributed equally to this work.

*Corresponding Author: Shu-shu Wang, School of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei, People's Republic of China. Email: wangss@ahtcm.edu.cn; Liang Wang, School of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei, People's Republic of China. Email: wangliang_01@163.com

Received: 24 February 2022; Accepted: 13 May 2022; Published: 16 June 2022

© 2022 Codon Publications

OPEN ACCESS SHORT COMMUNICATION

Abstract

Licorice (Glycyrrhiza glabra L.) is an essential herb in Chinese medicine, as well as a common ingredient in health foods and natural sweeteners. Liquiritin, the primary constituent of licorice, possesses a wide range of pharmacological and biological properties. This research aims to study the protective mechanism of liquiritin in the myocardium. The potential therapeutic efficacy of liquiritin against acute myocardial infarction (AMI) was tested using molecular docking and verified using an AMI rat model caused by the ligation of the LAD coronary artery. Molecular docking between liquiritin and toll-like receptor 4 (TLR4) and myeloid differentiation factor 88 (MyD88) was predicted using SystemsDock. Then, for experimental validation, in vivo studies were employed. Rats with the AMI model established by ligation of left anterior descending coronary artery were divided into four groups—sham group, model group, captopril group, and liquiritin group. LVSP, LVEDP, +dp/dtmax, and -dp/dtmax were detected and analyzed. HE and Masson staining were used to observe the pathological changes. The protein expressions of TLR4, MyD88, and nuclear factor κB p65 (NF-κB p65) were detected by Western blotting. Molecular docking showed that liquiritin may act on the TLR4 and MyD88, and, therefore, liquiritin was predicted to exert anti-inflammatory effects by regulating the TLR4/MyD88 signaling pathway. Liquiritin improved LVSP, +dp/dtmax, -dp/dtmax, and LVEDP levels, and alleviated pathological changes and cardiac fibrosis. Further study found that liquiritin could decrease the overexpression of TLR4, MyD88, and NF-κB, which validated the molecular docking study. Hence, liquiritin ameliorates AMI by reducing inflammation, and blocking TLR4/MyD88/NF-κB signaling. These results indicate that liquiritin as a potential compound could alleviate AMI and broaden its application.

Keywords: acute myocardial infarction; liquiritin; molecular docking; TLR4/MyD88/NF-κB signaling

Introduction

Acute myocardial infarction (AMI) is a major manifestation of ischemic heart disease (IHD), which is a leading cause of chronic heart failure (CHF) (Lin et al., 2020). As a serious cardiovascular event, AMI has become the leading cause of death in the world, which is characterized by high morbidity and mortality. Therefore, it needs to
be given enough attention, and it is particularly important to find an appropriate treatment (Yousufuddin et al., 2019). The occurrence of AMI is related to many factors, such as arrhythmia, severe inflammatory response, and cardiac dysfunction (Sinnecker et al., 2016). At present, the surgical treatment of AMI mainly includes reperfusion and revascularization therapy (Horikoshi et al., 2021). Restoring coronary blood flow to the infarcted myocardium can significantly reduce myocardial infarction; however, this process may further cause myocardial ischemia/reperfusion (I/R) injury, which causes secondary damage to AMI patients (Davidson et al., 2019; Yang et al., 2019). In spite of modern drugs for the prevention and treatment of AMI and improved public awareness, there is still a need for new and safe drugs to prevent AMI. Therefore, it is particularly important to find and develop new cardioprotective Traditional Chinese Medicine (TCM) for AMI patients.

Epidemiological evidence has suggested that diets rich in fruits and vegetables are associated with a lower incidence of cardiovascular diseases, as fruits and vegetables are rich in flavonoids and flavonoid glycosides (Krga et al., 2016; Zhou et al., 2020). Recent studies have found a positive correlation between higher intakes of flavonoids and reduced cardiovascular disease mortality (Yamagata, 2019). Licorice (Glycyrrhiza glabra L.) is an essential herb in Chinese medicine, which is also widely used in health foods and natural sweeteners (Jiang et al., 2020; Kwon et al., 2019). Licorice has anti-inflammatory, anti-obesity, anti-oxidant, anti-viral, and neuroprotective properties (Ahmed-Farid et al., 2019; Ojha et al., 2015; Sun et al., 2019). Flavonoids and flavonoid glycosides are one of the main chemical components of licorice. Liquiritin, as a flavonoid glycoside, is also one of the main components of licorice, which possesses anti-myocardial fibrosis, anti-cancer, anti-oxidative and neuroprotective effects (Huang et al., 2018; Sun et al., 2010; Wei et al., 2017). Previous studies have reported that liquiritin could suppress the levels of type I collagen, type II collagen, and alpha-smooth muscle-actin (α-SMA), reduce the release of inflammatory cytokines such as TNF-α, IL-6, and IL-17, and inhibit the protein expression of nuclear factor-κB (NF-κB) phosphorylation via regulating IKKα/IKKβ signaling pathway. It also has a protective effect against myocardial fibrosis (Zhang et al., 2016). Our previous studies found that liquiritin could directly inhibit ATE1 overexpression and inhibit TAK1 and JNK1/2 phosphorylation in H9c2 transfected by pcDNA3.1/ATE1, which plays a role in reducing Ang II-induced cardiomyocyte hypertrophy due to its regulation of ATE1/ TAK1-JNK1/2 pathway (Mo et al., 2022).

Toll-like receptor 4 (TLR4) can activate the expression of pro-inflammatory factors and chemokines by regulating the MyD88-dependent pathway, which affects many diseases, including cardiovascular diseases, allergic diseases, neuronal degeneration, and autoimmune diseases (He et al., 2019; Mian et al., 2019). Especially, in AMI, the pathogenesis is that the inflammatory response caused by activated TLR4 may be because of the TLR4-Myd88-dependent signaling pathway. Molecular docking can predict the potential target of the natural products, and then verify it through experiments, which can explain the mechanism of action of the natural products from Chinese Medicine.

Therefore, in this study, molecular docking technology was used to find whether liquiritin is a potential inhibitor of TLR4 and Myd88. The purpose of this study was to screen liquiritin for potential therapeutic targets for TLR4 and Myd88 through molecular docking, then determine possible pathological pathways, find the mechanism of interaction between liquiritin and receptors, and confirm results by an in vivo assay.

### Materials and Methods

#### Animals

Sprague-Dawley (SD) rats (Male, weight 200±20 g, SCXK 2017-001) were purchased from the Experimental Animal Center of Anhui Medical University. All rats were housed under 23±2°C, 12/12 h light/dark cycles. All experimental procedures were followed by the Center of Scientific Research of Anhui University of Chinese Medicine.

#### Chemicals

Liquiritin was purchased from Shanghai Yuanwe Biotechnology Company (Shanghai, China), and the purity was greater than 98%. TLR4 was from Affinity Bioreagents (Golden, CO). MyD88 and NF-κB p65 were from Abbkine (China).

#### Molecular docking

The liquiritin structure was obtained from the PubChem website. TLR4 (PDB ID: 3VQ2) (Ohto et al., 2012) and MyD88 (PDB ID: 4DOM) (Snyder et al., 2013) structures were obtained from RCSB (www.rcsb.org/pdb). SystemsDock was used for molecular docking (Hsin et al., 2016). The method of molecular docking consisted of four major steps: (1) Upload docking protein receptors. (2) Prepare chemical molecules for docking. The structural file is uploaded in 2D SDF format. (3) Run docking simulation. The docking simulation is carried out with machine learning system. (4) Acquire
molecular docking results including map information and pKd/pKi.

In vivo anti-acute myocardial infarction properties

Establishment of rat models
AMI model in rats with left anterior descending (LAD) coronary artery ligation as we have previously described (Raj et al., 2017; Wang et al., 2020). To reduce pain, all rats were anesthetized with isoflurane and ventilated artificially using a respirator. The AMI rat model was prepared by ligating a 6-0 silk suture with LAD 2 mm below the apex of the left atrial appendage. In the control group, rats were perforated but not ligated. After surgery, each rat was injected subcutaneously with 100,000 IU of penicillin to prevent infection and to increase the survival rate. The survival rate of both the sham group and the model group exceeded 90%.

Drug treatment
The control group received deionized water. Two weeks following the establishment of the AMI model, the AMI rats were randomized into three groups. The model group received deionized water, the captopril group received 3375 mg/kg of captopril, and the liquiritin group received 200 mg/kg of liquiritin. All rats were administered the intervention for four weeks. The captopril and liquiritin groups were gavaged once per day.

Measurement of hemodynamic indexes
Thirty minutes after the last treatment, all rats were sacrificed, and polystyrene was catheterized through the right carotid artery into the left ventricle of the heart. LVSP, LVEDP, +dp/dtmax, and -dp/dtmax were detected and analyzed by PowerLab (AD Instruments, Castle Hill, Australia).

Myocardial histopathology
Left ventricular myocardium containing myocardial infarction area was collected, and fixed with 4% paraformaldehyde. Thick tissue sections (4 μm) were prepared using paraffin-embedded tissues. Hematoxylin-eosin (HE) and Masson staining were used to observe the pathological changes.

Western Blotting
The concentration of myocardium-isolated total protein was determined using the BCA technique. Proteins were separated by SDS-PAGE, transferred to a nitrocellulose membrane, blocked in 5% nonfat dry milk for 2 h, and incubated overnight. The proportions of antibodies were TLR4 (1:1000), MyD88 (1:1000), and NF-κB p65 (1:1000). After incubating the membranes overnight at 4°C, the secondary antibodies were administered for 2 h at room temperature. After washing three times with TBST, electrogenerated chemiluminescence (ECL) was employed to develop and fix the gels, and a gel imager (FluorChem M, ProteinSimple, USA) was utilized for photographing the gels and performing a semiquantitative analysis. The experiment was repeated three times. β-actin was used as an internal control.

Statistical analysis
All data were analyzed using SPSS 23.0, with a significance level at P < 0.05. Multiple groups were compared by one-way analysis of variance and the LSD method. GraphPad Prism 5.0 was applied to all statistical analyses.

Results

Molecular docking of liquiritin with the biological targets

The docking score (pKd/pKi) between liquiritin and TLR4 was 6.28, which was slightly lower than the native ligand (7.35) (Table 1 and Figure 1). And, the docking score between liquiritin and MyD88 was 5.73, which was higher than the native ligand (4.18) (Table 2 and Figure 2). The binding affinity between liquiritin and TLR4 or MyD88 is mainly intermolecular hydrogen bond. The findings of the molecular docking prediction indicated that liquiritin may function on the TLR4/MyD88 signaling pathway; however, in vivo animal investigations are required to verify these results.

Liquiritin improves heart function
LVSP, +dp/dtmax, and -dp/dtmax in the model group were decreased (P < 0.01), while LVEDP significantly increased compared with the sham group (P < 0.01). LVSP, +dp/dtmax, -dp/dtmax, and LVEDP in the liquiritin and captopril groups reversed the results compared to the model group (P < 0.01) (Figure 3). The results indicated that

<table>
<thead>
<tr>
<th>Chemical constituents</th>
<th>Docking score</th>
<th>Binding of ligands to residues</th>
</tr>
</thead>
<tbody>
<tr>
<td>Native ligand</td>
<td>7.35</td>
<td>Ile124, Glu122, Ser413, Phe151, Phe438, Phe126, Leu54, Val82, Leu87, Arg90, Phe121, Ile153</td>
</tr>
<tr>
<td>Liquiritin</td>
<td>6.28</td>
<td>Ile124, Ser413, Phe438, Leu54, Arg90, Phe121, Ile52</td>
</tr>
</tbody>
</table>

Bold means residue binding except for native ligand.
clear, arranged in an orderly manner, and the direction was consistent. A small amount of collagen fibers with uniform distribution could be observed in the sham group. Cardiac fibrosis was increased in the model group, while it was improved greatly in the captopril and liquiritin groups (Figure 5).

Effect of liquiritin on the expression of TLR4, MyD88, and NF-κB p65

Western blotting was used to measure the expression in the TLR4/MyD88/NF-κB signal pathway. As shown in Figure 6, the expression of TLR4, MyD88, and NF-κB p65 were significantly increased in the model group compared with the sham group (P < 0.01; P < 0.05). The expression of TLR4, MyD88, and NF-κB p65 were obviously decreased in the liquiritin group and the captopril group compared with the model group (P < 0.01; P < 0.05), but there were no significant differences between the liquiritin group and the captopril group.

Discussion

Myocardial inflammation plays a key role in the physiological and pathological mechanism of cardiac function and dysfunction. Myocardial inflammation is a general double-edged sword. Effective and appropriate inflammation is necessary and beneficial for host defense against injury. Excessive or chronic inflammation can cause severe myocardial damage to the myocardium, such as AMI (Liu et al., 2019). AMI is a disease that causes damage and death to heart tissue due to the blockage of myocardial coronary arteries caused by atherosclerotic clots or arterial spasms, and now AMI has become one of the most common diseases that cause
morbidity and mortality worldwide. At present, the treatment of AMI mainly includes drug therapy, vascular reconstruction, and rehabilitation therapy, but these treatments have limited effect and find it difficult to prevent the progress of AMI (Amosse et al., 2017). Although revascularization can effectively alleviate AMI, it is also accompanied by intractable complications, such as no-reflow after percutaneous coronary intervention (PCI), intrastent thrombosis, ischemia-reperfusion injury, etc. (Hernandez-Resendiz et al., 2018). Therefore, it is of great significance for the development of new drugs to find effective therapeutic methods according to the pathogenesis of AMI. With the frequent and successful use of TCM in the prevention and treatment of AMI, the impact of Chinese medicine on AMI has drawn increasing attention.

As a “functional food,” flavonoids can be widely used in the prevention and treatment of cardiovascular diseases. The anti-inflammatory effect of flavonoids can be used to prevent and treat CVDs found in fruits, vegetables, grains, bark, flowers, and tea (Choy et al., 2019; Mozaffarian and Wu, 2018). Licorice contains multiple flavonoids, which possess a variety of biological activities.

Figure 2. The pictures of native ligand and active site of MyD88. Native ligand (A, 2D), Liquiritin (B, 2D).

Figure 3. Liquiritin improves hemodynamics dysfunction on (A) LVSP; (B) +dp/dtmax; (C) -dp/dtmax; (D) LVEDP. The values are expressed as mean ± SD (n = 10). **P < 0.01 versus Sham group, ##P < 0.01 versus Model group.
Figure 4. Morphological analysis of myocardial tissue stained with HE (×100). (A) Sham group. (B) Model group. (C) Captopril group. (D) Liquiritin group.

Figure 5. The Masson results of myocardium in different groups (×100). (A) Sham group. (B) Model group. (C) Captopril group. (D) Liquiritin group.
is stimulated by inflammatory signals, MyD88 binds to the cytoplasmic domain of TLR4 and activates IKK. Activated IKK kinase leads to phosphorylation and degradation of IκB in the proteasome, and NF-κB is then released from the NF-κB complex and transported to the nucleus, resulting in gene expression of pro-inflammatory cytokines (Yang et al., 2016). Activation of TLR4/MyD88 signaling pathway leads to direct activation of NF-κB and promotes secretion of pro-inflammatory cytokines. In this study, liquiritin decreased the expression of TLR4, MyD88, and NF-κB p65 proteins, suggesting that liquiritin inhibited AMI through TLR4/MyD88/NF-κB signaling pathway.

However, the current study has several limitations. First of all, this study only adopted an in vivo experiment, without further verification by an in vitro cell experiment. Secondly, this study lacked the use of TLR4 inhibitor, so as to better explore the mechanism of action of liquiritin on AMI.

Conclusion

In conclusion, molecular docking combined with in vivo evaluation showed that liquiritin has a cardioprotective effect on AMI model rats by inhibiting the TLR4/MyD88/NF-κB signaling pathway. This pathway may be a new
potential therapeutic target of liquiritin in the treatment of AMI, and these properties of liquiritin can be further explored to develop viable anti-AMI agents.

**Declarations**

**Funding**

Financial assistance was received with appreciation from the National Natural Science Foundation of China (No. 82004180), Key Project Foundation of Natural Science Research in Universities of Anhui Province in China (KJ2020A0411), and the Key Project Foundation of Natural Science Research of Anhui University of Chinese Medicine (2020zrzd06 and 2021zrzd22).

**Conflict of Interest**

The authors declare that they have no conflict of interest.

**Data Availability Statement**

The data that support the findings of this study are available from the corresponding author upon reasonable request.

**References**


Mian, M.O.R., He, Y., Bertagnoli, M., Mai-Yo, T.A., Fernandes, R.O. and Boudreau, F., 2019. TLR (Toll-Like Receptor) 4 antagonism
prevents left ventricular hypertrophy and dysfunction caused by neonatal hyperoxia exposure in rats. Hypertension 74: 843–853. https://doi.org/10.1161/HYPERTENSIONAHA.119.13022


